CN1269720A - Method of increasing bone volume - Google Patents
Method of increasing bone volume Download PDFInfo
- Publication number
- CN1269720A CN1269720A CN98808884A CN98808884A CN1269720A CN 1269720 A CN1269720 A CN 1269720A CN 98808884 A CN98808884 A CN 98808884A CN 98808884 A CN98808884 A CN 98808884A CN 1269720 A CN1269720 A CN 1269720A
- Authority
- CN
- China
- Prior art keywords
- agonist
- prostaglandin
- application according
- receptor
- bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 67
- 230000001965 increasing effect Effects 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title abstract description 23
- 239000000556 agonist Substances 0.000 claims abstract description 38
- 102000003923 Protein Kinase C Human genes 0.000 claims abstract description 22
- 108090000315 Protein Kinase C Proteins 0.000 claims abstract description 22
- 239000011575 calcium Substances 0.000 claims abstract description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 33
- 238000013459 approach Methods 0.000 claims description 26
- 150000003180 prostaglandins Chemical class 0.000 claims description 23
- 102000000471 Prostaglandin F receptors Human genes 0.000 claims description 21
- 108050008995 Prostaglandin F receptors Proteins 0.000 claims description 21
- 208000001132 Osteoporosis Diseases 0.000 claims description 14
- 210000000963 osteoblast Anatomy 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 12
- 102000015433 Prostaglandin Receptors Human genes 0.000 claims description 10
- 108010050183 Prostaglandin Receptors Proteins 0.000 claims description 10
- WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims description 10
- 229950009951 fluprostenol Drugs 0.000 claims description 10
- 206010022998 Irritability Diseases 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000008416 bone turnover Effects 0.000 claims description 4
- DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 claims description 4
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 3
- 208000027868 Paget disease Diseases 0.000 claims description 3
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 3
- 229960001160 latanoprost Drugs 0.000 claims description 3
- 208000027202 mammary Paget disease Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 3
- FYBFDIIAPRHIQS-KKBLUXBBSA-N (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-thiophen-3-yloxybut-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC=1C=CSC=1 FYBFDIIAPRHIQS-KKBLUXBBSA-N 0.000 claims description 2
- 208000010392 Bone Fractures Diseases 0.000 claims description 2
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 2
- 206010017076 Fracture Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229950004900 alfaprostol Drugs 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 229960004409 cloprostenol Drugs 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229950007806 delprostenate Drugs 0.000 claims description 2
- 229940032383 estrumate Drugs 0.000 claims description 2
- 229950004738 froxiprost Drugs 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- FNAMRDZHKYQEBA-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 FNAMRDZHKYQEBA-YDQNNXAVSA-N 0.000 claims description 2
- REFZGTXXBBUTMJ-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 REFZGTXXBBUTMJ-YDQNNXAVSA-N 0.000 claims description 2
- OZDSQCVLNUIYLN-JNAAKWLTSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-JNAAKWLTSA-N 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 claims description 2
- MUVLUMTZYKYXRV-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(C(F)(F)F)=C1 MUVLUMTZYKYXRV-KXXGZHCCSA-M 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 229950002099 tiaprost Drugs 0.000 claims description 2
- 230000004913 activation Effects 0.000 abstract description 11
- 208000020084 Bone disease Diseases 0.000 abstract description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 2
- 230000037361 pathway Effects 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000001582 osteoblastic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108010048734 sclerotin Proteins 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000005486 microgravity Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091006068 Gq proteins Proteins 0.000 description 1
- 102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002968 anti-fracture Effects 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MVQBFZXBLLMXGS-UHFFFAOYSA-N chembl331220 Chemical compound C1=CC=C2C(N=NC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C=C(S(O)(=O)=O)C2=C1 MVQBFZXBLLMXGS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000704 endosteal cell Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to novel methods of increasing bone volume comprising activating the osteoblastic protein kinase C/intracellular calcium pathways of a subject. This invention further relates to a method of treating or preventing bone disorders wherein activation occurs by the administration of a FP agonist.
Description
Technical field
The present invention relates to increase the new method of bone volume, these methods comprise the osteoblast Protein kinase C/cellular calcium approach that activates object.The invention still further relates to the method for a kind of treatment or prevention osteopathia, wherein activation produces by giving the FP agonist.
Background of invention
In osteoporosis, produced a kind of imbalance in the bone process of reconstruction, the speed of bone absorption is faster than osteoplastic speed.Although in most of individualities (masculinity and femininity has), along with to a certain degree this energy imbalance all can appear in their aging, but it is even more serious in younger patients with osteoporosis, especially suffers among those patients of postmenopausal osteoporosis form.Bone loss quicken also may since take that medicine (for example 17-hydroxy-11-dehydrocorticosterone), bed rest time are long, limbs give up with and microgravity cause.The consequence of bone loss is that bone trabecula is removed and the bone structure deterioration fully, thereby the intensity of its bone that stays is disproportionately reduced.
Think to make bone return back to normal intensity fully, just should form new bone trabecula, to recover bone structure and to increase the bone amount.Think that also when the intensity increase has not only been followed in the recovery of normal configuration, but also followed when returning to normal rigidity and cushioning ability, then Gu Zhe probability is just littler.Suffering from the object of other osteopathia (as osteoarthritis, Paget disease, periodontal disease and fracture) also can be benefited from the treatment that recovers bone amount and normal bone structure.
People have attempted treating osteopathia with various pharmaceutically active compounds, and purpose is to slow down that sclerotin is further lost or the net increase bone mass.For example, have and only slow down the anti-absorbent (as diphosphonate) that sclerotin is further lost.In addition, known bone assimilation agent is arranged, as PTH and PGE
2But, do not have a kind of medicine can construct with the type of the bone lost structurally or textural closely similar bone.
Known PTH and PGE
2All stimulate cAMP and Protein kinase C/cellular calcium approach.Usually, think that it is essential stimulating the cAMP approach, and be enough to build bone.This idea to small part has increased bone trabecula thickness according to the PTH analog that only improves cAMP, and the PTH analog that only increases PKC/Ca++ does not increase the observation of bone amount.This idea is also according to such observed result, that is, and and the main and link coupled EP of cAMP approach of selective stimulating
2The PGE of receptor
2Analog has increased bone volume.PCT publication WO 98/27976.
Except the very dissimilar bone of the bone type that builds and lose, these known assimilation agent are (as PTH and PGE
2) also have several shortcomings, thus limited their satisfactions in the whole body administration.For example, at specific prostaglandin receptor place activity is arranged although the feature of prostaglandin is them, their activity is not limited to arbitrary prostaglandin receptor.Therefore, the whole body administration meeting of known prostaglandin causes side effect, as inflammation and surface stimulation, smooth muscle contraction, bronchoconstriction and vasoconstriction.The whole body administration of nonselective prostaglandin analogue can cause side effect equally.
Therefore, still need to develop a kind of method that makes bone recovery, produce structurally and the textural bone that is substantially similar to the bone type of losing.
Summary of the invention
Find unexpectedly that the medicine that mainly activates osteoblast Protein kinase C/cellular calcium approach has obviously improved bone mass than other assimilation agent.Good especially medicament is to FP receptor medicament selectively.Good for especially the FP receptor naturally occurring FP agonist of medicament right and wrong selectively.The FP agonist that good especially non-natural exists is to the selectivity ratios of the FP receptor selectivity height to other irritability prostaglandin receptor, and optionally ratio is at least about 1: 10, and is better for 1: 20, best at least about 1: 50.Also want FP agonist that good non-natural exists to the selectivity ratios of the FP receptor selectivity height to other all prostaglandin receptoroids, the ratio of selectivity is at least about 1: 10, and is better for 1: 20, best at least about 1: 50.
Also further find, the main medicament that activates osteoblast Protein kinase C/cellular calcium approach has increased the bone trabecula number by forming new bone trabecula, increased bone volume and bone amount and kept normal bone turnover rate simultaneously, and increased the formation on perimyelis surface and do not remove sclerotin in the existing cortex.
Therefore, the present invention relates to increase the method for bone volume, increase the method for bone trabecula number and the method for treatment osteopathia, these methods are mainly to activate osteoblast Protein kinase C/cellular calcium approach.
Accompanying drawing describes in detail
Fig. 1 shows Ca in Protein kinase C/born of the same parents
++Approach.
Detailed Description Of The Invention
The present invention relates to increase the method for bone volume, increase the method for bone trabecula number and the method for the treatment of bone disease, method is mainly to activate Gegenbaur's cell protein kinase C/cellular calcium approach (＂ PKC/Ca++Approach ＂).
The definition of term and use
Term used herein " the Gegenbaur's cell protein kinase C of activation object/cellular calcium approach " refers to, activate and 7 Gq protein families that transmembrane receptor protein is relevant, this activation has caused and has contained protein kinase C (PKC) and Ca++Born of the same parents in courier's cascade reaction.
Term used herein " assimilation agent " refers to increase the medicament of sclerotin.
The disease that term used herein " osteopathia " phalanges need be repaired or replenish.May need the bone reparation or the additional state of an illness to comprise: osteoporosis (comprises postmenopausal osteoporosis, the inductive osteoporosis of masculinity and femininity senile osteoporosis and 17-hydroxy-11-dehydrocorticosterone), osteoarthritis, the Paget disease, the osteomalacia, the cancer of multiple myeloma and other form, CBR, the chronic useless usefulness of limbs, apositia, microgravity (microgravity), external source and endogenous gonad insufficiency, fracture, nonunion, damaged, prosthese reparation implantation etc.
Term used herein " bone turnover rate " refers to bone resorption and the formation in the time per unit, and fluorescent marker participates in the bone by making for it, fluorescence and bright field microscopy and tissue morphology measurement's (histomorphometry) technology or measure or estimate by measuring the bone metabolism label.For example, object may absorb in 3 months and its skeleton of about 3% that replenished (renewal).About finding in further describing of tissue morphology measurement's technology can be write people such as Eriksen, Raven publishing house published in 1994 " bone histomorphometry ".
Term used herein " bone volume " refers to that mineralising substrate occupies the percent of bone.The mensuration of mineralising substrate capacity or estimate that available Morphometry, x-ray computer tomography or the magnetic resonance imaging organized realizes.Available two dimension is measured and is estimated three-dimensional capacity.About finding in further describing of tissue morphology measurement's technology can be write people such as Eriksen, Raven publishing house published in 1994 " bone histomorphometry ".
The prostaglandin receptoroid that term used herein " irritability prostaglandin receptor " has guided smooth muscle contraction or internal calcium storage storehouse to discharge.These receptors include, but are not limited to, FP, EP
1, EP
3, TP
1And TP
2
Term used herein " FP " is the abbreviation of prostaglandins F.
Term used herein " FP agonist " refers to the FP receptor is had the chemical compound of affinity, and it causes containing and produces the biological activity (including, but not limited to the rising or the smooth muscle contraction of cellular calcium level) that can measure in cell, tissue or the organism of FP receptor.The active full cell of proof compound F 17-hydroxy-corticosterone P, tissue and organism test are to know in this area.A kind of useful especially test be people such as Brann 1996 the 1st volume the 1st phase " biomolecular screening magazine " (J.Biomole.Screen) in the R-SAT of description
TMTest.
Term used herein " FP receptor " refers to known people FP receptor, their splice variant, and preferentially in conjunction with PGF
2 αThe receptor of not described.People FP receptor is disclosed among the PCT publication WO 95/00551.
Term used herein " can be measured (amount) " and refer to that biological effect is replicable, and obviously different with the baseline variability of test.
Term used herein " non-natural existence " refers to that medicament is not with the biological method acquisition of deriving from mammal.
Term used herein " osteoblast " refers to the cell of osteoblast pedigree, and it comprises precursor or CFU-GM, preosteoblast (pre-osteoblast), osteoblast, endosteal cell and osteocyte.
Term used herein " mainly " refer to, osteoblast PKC/Ca
++Approach is preferentially activated by medicament than cAMP approach.PKC/Ca
++Approach is measured than the available various experiment that preferentially is activated of cAMP approach.For example, can be used on that people such as Albert writes, the calcon-carboxylic acid Fura-2 of the 183rd page of description in " the cellular elements biology " of publishing in 1994 of Garland publishing house tests and measures intracellular Ca
++Concentration, cAMP in the cell is measured in the test that people such as available J Bilezikian write, describe among 1205 pages of the Academic Press 1996 " bone biology principle ".For direct these two approach relatively, activate than being 1 to be defined as: 100% PGE
2To PKC/Ca
++The maximum activation effect of approach is divided by 100% PEG
2Activation to the cAMP approach.Reach the required PGE of maximum activation
2Concentration may differ from two orders of magnitude.Priority activation will represent that this ratio is increased to and be higher than 1, and preferable is approximately higher than 2, and better is approximately higher than 3.5, and best is approximately higher than 5, and wherein the pathway activation agent can increase PKC/Ca
++The activation of approach is (for example to PGE
2125%) or the activation that reduces the cAMP approach (for example to PGE
275%).
Term used herein " prostaglandin analogue " refers to the chemical compound that structurally similar to prostaglandin non-natural exists.
Term used herein " prostaglandin receptor " or " prostaglandin receptoroid " refer to the naturally occurring albumen in conjunction with prostaglandin, it in conjunction with the time changed the function of cell.Prostaglandin receptor can be characterized by irritability or releiving property.These receptors include, but are not limited to, FP, EP
1, EP
2, EP
3, EP
4, DP, IP, TP
1And TP
2People such as Coleman have further discussed these receptors at 1994 the 6th in volume the 2nd phase " pharmacology summary " (Pharmacological Reviews) the 205-229 page or leaf.
Term used herein " selectivity " refers to the activation of a specific receptor more preferential than other receptor, and this can test (as above-mentioned R-SAT according to full cell, tissue or the organism of proof receptor active
TMTest) comes quantitative assay.The selectivity of chemical compound is by comparing its EC on associated receptor
50(or ED
50If adopt the organism test) determine.For example, the EC of chemical compound on the FP receptor
50For 8nM, at EP
1EC on the receptor
50Be 80nM, it is to the FP receptor and to EP
1The selectivity ratio of receptor is 1: 10.
Term used herein " object " refers to the vertebrates of the work of needs treatment, as mammal (especially people).
Term used herein " bone trabecula number " refers to the individual bone trabecula number of per unit volume spongy bone, and it is measured by two dimension demonstration or three-dimensional sample with tissue morphology measurement's method, x-ray computer tomography or magnetic resonance imaging or estimates.
Chemical compound
Medicament of the present invention mainly activates osteoblast PKC/Ca
++Approach.Approach as shown in Figure 1.Be used for medicament of the present invention by the main osteoblast PKC/Ca that activates
++Approach increases bone volume.Good especially medicament is to FP receptor medicament selectively.To the naturally occurring FP agonist of the selectively good especially medicament right and wrong of FP receptor.The FP agonist that good especially non-natural exists to the FP receptor than its to the selectivity ratio of other irritability prostaglandin receptor at least about 1: 10, better for 1: 20, best at least about 1: 50.The FP agonist of also wanting good non-natural to exist, it is at least about 1: 10 to the FP receptor than its optionally ratio to all other prostaglandin receptoroids, and better is at least about 1: 20, best at least about 1: 50.
The selective FP agonist that useful especially non-natural exists is a prostaglandin analogue.The example of these chemical compounds is the prostaglandin analogues with following general formula:
Wherein:
R
1Be CO
2H, C (O) NHOH, CO
2R
2, CH
2OH, S (O)
2R
2, C (O) NHR
2, C (O) NHS (O)
2R
2, or tetrazolium; It is characterized in that R
2Be alkyl, assorted alkyl, carbocyclic ring aliphatic series ring, heterocycle aliphatic series ring, aromatic ring or hetero-aromatic ring;
X is (CH
2)
n, wherein n is 0 to 3, NH, S or O; With
Y replaces or unsubstituted cycloalkyl or aromatics part.
Prostaglandin analogue with said structure comprises: cloprostenol (Estrumate ), fluprostenol (Equimate ), tiaprost, alfaprostol, delprostenate, froxiprost, latanoprost (latanoprost), 13,14-dihydro-16-((3-trifluoromethyl) phenoxy group)-16-four loses carbon (tetranor) prostaglandin F
1α, 17-((3-trifluoromethyl) phenyl)-17-three loses carbon (trinor) prostaglandin F
2α, 13,14-dihydro-18-thienyl-18-two loses carbon (dinor) prostaglandin F
1α and their analog.
Other prostaglandin analogue of the present invention comprises 9-α, 11-α, and 15-α-trihydroxy-16-(3-chlorophenoxy)-ω-four loses carbon-prostatitis-4-suitable-13-is anti--dienoic acid and analog thereof.Other prostaglandin analogue also is disclosed in " quasi-arachidonic acid CRC handbook: prostaglandin and relevant lipid " (CRC Handbook of Eicosanoids:Prostaglandinsand Related Lipids, the I volume, Chemical and Biochemical Aspects, B portion, Anthony L.Willis, CRC Press (Boca Raton, 1987) table 4, the 80-97 page or leaf, it is for referencial use to include this paper in) and list of references in.
Using method
Above-mentioned medicament can be used to increase bone volume, increases the bone trabecula number by forming new bone trabecula, increases bone weight and does not increase the bone turnover rate, increases the formation on perimyelis surface and does not remove sclerotin in the existing cortex.In addition, by giving bone mass that these medicaments form than good by giving the bone mass that other bone assimilation agent (prostaglandin that comprises E series) forms.This bone mass (quality) be meant bone matrix (inorganic and organically), bone amount or capacity, influence the combination of the bone structure of bulk strength and anti-fracture performance.Therefore, these medicaments also can be used for treatment and prevent various osteopathias.
Being used for increasing bone volume is percutaneous and subcutaneous administration with the preferable route of administration for the treatment of osteopathia, for example injection or micropill.That other preferable route of administration comprises is oral, Sublingual and intranasal administration.
The dosage range that whole body gives the FP agonist that non-natural of the present invention exists is about 0.01-1000 microgram/kg body weight every day, preferably every day about 0.05-100 microgram/kg body weight, the best be about 0.1-50 microgram/kg body weight every day.Estimate blood plasma level in about 0.01-500ng/ milliliter scope, better in about 0.05-100ng/ milliliter scope, the best in about 0.1-50ng/ milliliter scope.
Although these dosage are according to administration every day ratio, integral dose also weekly available or every month calculates clinical demand.The FP agonist that non-natural of the present invention exists can be than frequent drug administration (in a weekly dose) more once a day.The FP agonist that non-natural of the present invention exists also can be not so good as once a day frequent drug administration (in a weekly dose) like that.Therefore, a weekly dose can be divided into 3,4,5,6 or 7 parts every day dosage, preferably be divided into 5,6 or 7 parts every day dosage.
Dosage can be according to subject patient, the subject state of an illness, treated the order of severity of the state of an illness and realize that the route of administration of required effect becomes.
Find further that also the FP agonist that non-natural exists prolongs administration (being also referred to as " prolong and carry ") and unexpectedly produced side effect and the isolating improved administering effect of required bone effect.In other words, term used herein " prolongation administration " or " prolong carry " refer at least about 6 hours to the highest 24 hours, and the accumulated dose of every day is conveyed in the blood circulation of object.The preferable prolongation conveying phase is at least about 12 hours to the highest 24 hours.The example that prolongs administration comprises that percutaneous patch or subcutaneous pump by can carry accumulated dose every day in 24 hours give the FP agonist that non-natural exists.
It is believed that prolonging plasma concentration curve that administration caused flattens and alleviated side effect, has kept the effect of bone simultaneously.Also believe, give FP agonist that the non-natural of long half time exists and can cause the plasma concentration curve to flatten equally and need not prolong administration.
Following non-restrictive example helps to further describe the application of medicament of the present invention.
Embodiment 1
Give 65 years old old woman that the bone amount reduces and diagnose through the doctor trouble osteoporosis with FP agonist fluprostenol.She accepts the treatment of percutaneous patch every day, and this patch was carried the fluprostenol of 10 microgram/kilograms (body weight) in 24 hours.Continue this treatment 24 months, this moment, (dual energy X-ray absorptiometry DXA) measured, and the vertebrae amount when its vertebrae amount begins with treatment is compared greatly and increased through double energy X line absorption algoscopy.
Example II
Give 63 years old old woman that the bone amount reduces and diagnose through the doctor trouble osteoporosis with FP agonist fluprostenol.She accepts the treatment of implantable subcutaneous pump, and this subcutaneous pump was carried the fluprostenol of 10 microgram/kilograms (body weight) in 24 hours.Continue this treatment 12 months, at this moment, measure through double energy X line absorption algoscopy, the vertebrae amount when its vertebrae amount begins with treatment is compared greatly and is increased.
Pharmaceutical formulation
Pharmaceutical formulation of the present invention comprises the FP agonist and the pharmaceutically acceptable carrier of the non-natural existence of safe and effective amount.
" safe and effective amount " refer in this article, and in rational medical assessment scope, the amount height of chemical compound or compositions must be enough to obviously improve the symptom and/or the state of an illness of being treated, but low be enough to avoid serious adverse (have rational curative effect/risk than).The pharmacy security effective dose that is used for the inventive method will be according to the factor in age of the concrete state of an illness of receiving treatment, the patient that receives treatment and the order of severity of physical condition, the state of an illness, the persistent period of treatment and the treatment situation of depositing, the concrete medicament that uses, the concrete doctor's knowledge and skills scopes such as pharmaceutically acceptable excipient used and different.
Except that chemical compound, the present composition also comprises pharmaceutically acceptable carrier." pharmaceutically acceptable carrier " refers to that in this article one or more are fit to give compatible solid or the liquid filling diluent or the encapsulation material of object.Term " compatible " refers to that at this component can be admixed each other mutually with chemical compound and their in compositions, and the interaction of compositions drug effect does not take place obviously to reduce under general operating position the mode of this blending.Certainly, pharmaceutically acceptable carrier must have sufficiently high purity and enough low toxicity, so that be fit to treat subject object.
Some examples that can be used as the material of pharmaceutically acceptable carrier or component have sugar, for example lactose, dextrose plus saccharose; Starch, for example corn starch and potato starch; Cellulose and derivant thereof, for example sodium carboxymethyl cellulose, ethyl cellulose, cellulose ethanoate; Powdered tragacanth; Fructus Hordei Germinatus; Gelatin; Talcum; Kollag, for example stearic acid, magnesium stearate; Calcium sulfate; Vegetable oil, for example Oleum Arachidis hypogaeae semen, Oleum Gossypii semen, Oleum sesami, olive oil, Semen Maydis oil, cupu oil; Polyhydric alcohol, for example propylene glycol, glycerol, sorbitol, mannitol and Polyethylene Glycol; Alginic acid; Emulsifying agent, for example tween ; Wetting agent, for example sodium lauryl sulphate; Coloring agent; Flavoring agent; Excipient; Tablet agent; Stabilizing agent; Antioxidant; Antiseptic; Apirogen water; Isotonic saline solution and phosphate buffer.
The selection of the pharmaceutically acceptable carrier that is used in combination with chemical compound is determined according to the administering mode of chemical compound basically.The FP agonist that non-natural of the present invention exists can the whole body administration, comprises percutaneous dosing, oral and/or parenteral, comprises subcutaneous or intravenous injection and/or intranasal administration.
The suitable amounts of medicament to be used (the preferably FP agonist of non-natural existence) can be determined with the normal experiment method of animal model.This model includes, but are not limited to, and suffers from the complete ovariectomized rat model of osteoporosis, the useless model of using of suffering from ferret, dog and the non-human primates model and the osteoporosis of osteoporosis.
The preferred methods that gives the FP agonist of non-natural existence is a percutaneous dosing.Preferable percutaneous dosage form comprises percutaneous patch, emulsifiable paste, ointment, gel etc.Another preferred methods that gives the FP agonist of non-natural existence is to make subcutaneous injection by unit dosage forms.The preferable unit dosage forms that is used to inject comprises the solution of sterilized water, normal saline or their mixture.The pH of described solution should be adjusted to and be about 7.4.
Other preferable dosage form comprises nose, rectum, Sublingual and peroral dosage form.Be used to inject or suitable carrier that surgery is implanted comprises hydrogel, control or delayed release device, polylactic acid (polylactic acid) and collagen stroma.Implanting device can apply with the FP agonist that non-natural exists.The prostaglandin F P agonist that non-natural exists can be dissolved in the buffer, and mix, be coated to then on the multi-apertured end of implanting device with collagen gel.
Preferable peroral dosage form comprises, for example liposome, lipid Emulsion, albumen skeleton (proteinaceous cage) and pharmaceutically acceptable excipient.
Term used herein " pharmaceutically acceptable excipient " comprises any physiology well known by persons skilled in the art material inert, non-activity on pharmacology, and it is compatible with the physics and the chemical characteristic of the concrete active component of selecting to use.Pharmaceutically acceptable excipient comprises, but be not limited to polymer, resin, plasticizer, filler, lubricant, binding agent, disintegrating agent, solvent, cosolvent, buffer system, surfactant, antiseptic, sweetener, flavoring agent, medicinal pigment and pigment.
Following non-limiting examples has been described prescription of the present invention.
EXAMPLE III
Use conventional method, as mixing and direct compression, make the pharmaceutical formulation (compositions) of tablet form, its prescription is as follows:
Amounts of components (milligram/sheet)
Fluprostenol 5
Microcrystalline Cellulose 100
Explotab 30
Magnesium stearate 3
Every day oral above-mentioned tablet once, continue 6 months, the bone volume of suffering from the patient of osteoporosis increases greatly.
EXAMPLE IV
Make the pharmaceutical composition of liquid form with conventional method, its prescription is as follows:
Amounts of components
5 milligrams of cloprostenols
10 milliliters of phosphate buffered salines
0.05 milliliter of methyl butex
Every day is subcutaneous to give 1.0 milliliters of above-mentioned compositions once, continues 6 months, and the bone volume of suffering from the patient of osteoporosis increases greatly.
Although described specific embodiments of the present invention, those skilled in the art obviously can not break away from the spirit and scope of the present invention and compositions disclosed herein are done various variations and change.
Claims (23)
1. the medicine that mainly activates the osteoblast Protein kinase C/cellular calcium approach of object is used for increasing the application of the medicament of bone volume in the subject in production.
2. the medicine that mainly activates the osteoblast Protein kinase C/cellular calcium approach of object is used for increasing the application of the medicament of bone trabecula number in the subject in production.
3. the medicine that mainly activates the osteoblast Protein kinase C/cellular calcium approach of object is used for the treatment of application in the medicament of object osteopathia in production.
4. according to claim 1,2 or 3 described application, it is characterized in that the naturally occurring selective FP agonist of medicine right and wrong.
5. application according to claim 4 is characterized in that, the FP agonist that non-natural exists is compared other irritability prostaglandin receptor to the FP receptor and had more selectivity, and selectivity ratio was at least 1: 10.
6. application according to claim 5 is characterized in that, the FP agonist that non-natural exists is compared other all prostaglandin receptoroids to the FP receptor and had more selectivity, and selectivity ratio was at least 1: 10.
7. application according to claim 6 is characterized in that, the FP agonist that non-natural exists is compared other irritability prostaglandin receptor to the FP receptor and had more selectivity, and selectivity ratio was at least 1: 20.
8. application according to claim 7 is characterized in that, the FP agonist that non-natural exists is compared other all prostaglandin receptoroids to the FP receptor and had more selectivity, and selectivity ratio was at least 1: 20.
9. application according to claim 8 is characterized in that, the FP agonist that non-natural exists is compared other irritability prostaglandin receptor to the FP receptor and had more selectivity, and selectivity ratio was at least 1: 50.
10. application according to claim 9 is characterized in that, the FP agonist that non-natural exists is compared other all prostaglandin receptoroids to the FP receptor and had more selectivity, and selectivity ratio was at least 1: 50.
11. application according to claim 10 is characterized in that, the FP agonist that non-natural exists is a prostaglandin analogue.
12. application according to claim 11 is characterized in that, the FP agonist that medicament allows percutaneous to carry non-natural to exist.
13. application according to claim 11 is characterized in that, prostaglandin has following general formula:
It is characterized in that:
R
1Be CO
2H, C (O) NHOH, CO
2R
2, CH
2OH, S (O)
2R
2, C (O) NHR
2, C (O) NHS (O)
2R
2, or tetrazolium; Feature is R
2Be alkyl, assorted alkyl, carbocyclic ring aliphatic series ring, heterocycle aliphatic series ring, aromatic ring or hetero-aromatic ring;
X is (CH
2)
n, wherein n is 0 to 3, NH, S or O; With
Y replaces or unsubstituted cycloalkyl or aromatics part.
14. application according to claim 11 is characterized in that, prostaglandin analogue is a fluprostenol.
15. application according to claim 14 is characterized in that, medicament allows percutaneous to carry fluprostenol.
16. application according to claim 8, it is characterized in that, the FP agonist that non-natural exists is selected from cloprostenol (Estrumate ), fluprostenol (Equimate ), tiaprost, alfaprostol, delprostenate, froxiprost, 9-α, 11-α, 15-α-trihydroxy-16-(3-chlorophenoxy)-ω-four loses carbon-prostatitis-4-suitable-13-is anti--and dienoic acid, 17-((3-trifluoromethyl) phenyl)-17-three lose carbon-prostaglandin F
2α, 13,14-dihydro-18-thienyl-18-two loses the carbon prostaglandin F
1α, 13,14-dihydro-16-((3-trifluoromethyl) phenoxy group)-16-four loses the carbon prostaglandin F
1α, latanoprost and their analog.
17. application according to claim 3 is characterized in that, osteopathia is selected from osteoporosis, osteoarthritis, Paget disease, osteomalacia and fracture.
18. application according to claim 3 is characterized in that, osteopathia is an osteoporosis.
19. application according to claim 18 is characterized in that, the FP agonist that non-natural exists is a fluprostenol.
20. application according to claim 18 is characterized in that, osteopathia is a postmenopausal osteoporosis.
21., it is characterized in that medicament allows to prolong the FP agonist that gives the non-natural existence according to claim 1,2 or 3 described application.
22. application according to claim 20 is characterized in that, medicament allows to carry the FP agonist of non-natural existence at least 20 hours.
23., it is characterized in that medicament does not increase the bone turnover rate of object greatly according to claim 1,2 or 3 described application.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5821897P | 1997-09-09 | 1997-09-09 | |
| US60/058,218 | 1997-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1269720A true CN1269720A (en) | 2000-10-11 |
Family
ID=22015432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98808884A Pending CN1269720A (en) | 1997-09-09 | 1998-09-04 | Method of increasing bone volume |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1035853A1 (en) |
| JP (1) | JP2001515863A (en) |
| CN (1) | CN1269720A (en) |
| AR (1) | AR013478A1 (en) |
| AU (1) | AU9130298A (en) |
| BR (1) | BR9811775A (en) |
| CA (1) | CA2303799A1 (en) |
| CO (1) | CO5070621A1 (en) |
| HU (1) | HUP0003584A3 (en) |
| ID (1) | ID24759A (en) |
| IL (1) | IL134759A0 (en) |
| NO (1) | NO20001172L (en) |
| PE (1) | PE118899A1 (en) |
| PL (1) | PL339297A1 (en) |
| SK (1) | SK3402000A3 (en) |
| WO (1) | WO1999012550A1 (en) |
| ZA (1) | ZA988229B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1159266B1 (en) * | 1999-03-05 | 2004-11-03 | Duke University | C-16 unsaturated fp-selective prostaglandins analogs |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993015767A1 (en) * | 1992-02-05 | 1993-08-19 | Merck & Co., Inc. | Implant therapy for bone growth stimulation |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1998
- 1998-09-04 HU HU0003584A patent/HUP0003584A3/en unknown
- 1998-09-04 SK SK340-2000A patent/SK3402000A3/en unknown
- 1998-09-04 PL PL98339297A patent/PL339297A1/en unknown
- 1998-09-04 BR BR9811775-0A patent/BR9811775A/en not_active Application Discontinuation
- 1998-09-04 AU AU91302/98A patent/AU9130298A/en not_active Abandoned
- 1998-09-04 WO PCT/US1998/018337 patent/WO1999012550A1/en not_active Application Discontinuation
- 1998-09-04 CA CA002303799A patent/CA2303799A1/en not_active Abandoned
- 1998-09-04 EP EP98943532A patent/EP1035853A1/en not_active Withdrawn
- 1998-09-04 ID IDW20000638A patent/ID24759A/en unknown
- 1998-09-04 IL IL13475998A patent/IL134759A0/en unknown
- 1998-09-04 JP JP2000510447A patent/JP2001515863A/en not_active Withdrawn
- 1998-09-04 CN CN98808884A patent/CN1269720A/en active Pending
- 1998-09-08 AR ARP980104480A patent/AR013478A1/en not_active Application Discontinuation
- 1998-09-09 CO CO98051809A patent/CO5070621A1/en unknown
- 1998-09-09 PE PE1998000855A patent/PE118899A1/en not_active Application Discontinuation
- 1998-09-09 ZA ZA988229A patent/ZA988229B/en unknown
-
2000
- 2000-03-07 NO NO20001172A patent/NO20001172L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20001172D0 (en) | 2000-03-07 |
| NO20001172L (en) | 2000-05-08 |
| PL339297A1 (en) | 2000-12-04 |
| JP2001515863A (en) | 2001-09-25 |
| AU9130298A (en) | 1999-03-29 |
| HUP0003584A3 (en) | 2002-12-28 |
| ZA988229B (en) | 1999-03-09 |
| WO1999012550A1 (en) | 1999-03-18 |
| PE118899A1 (en) | 2000-02-03 |
| ID24759A (en) | 2000-08-03 |
| EP1035853A1 (en) | 2000-09-20 |
| CA2303799A1 (en) | 1999-03-18 |
| BR9811775A (en) | 2000-08-29 |
| SK3402000A3 (en) | 2000-12-11 |
| HUP0003584A2 (en) | 2001-02-28 |
| AR013478A1 (en) | 2000-12-27 |
| CO5070621A1 (en) | 2001-08-28 |
| IL134759A0 (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1269721A (en) | Method for increasing bone volumn using non-naturally-occuring EP selective agonists | |
| CN1135161A (en) | Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds | |
| CN1193911A (en) | Use of basic amino acids and derivatives for lowering ceramide levels | |
| EP2020999B1 (en) | Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance | |
| CN1269720A (en) | Method of increasing bone volume | |
| US20030158247A1 (en) | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor | |
| CN1233150A (en) | Method for inhibiting the expression of FAS | |
| US7238718B2 (en) | Method for treating myolytic disease and method for screening antimyolytic agent | |
| CN1293877C (en) | Neurotrophic tacrolimus analogs | |
| WO2000051585A2 (en) | Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume | |
| WO2000051616A1 (en) | Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives | |
| JPH1135470A (en) | Parathormone production promoter containing vitamin d3 derivative | |
| CN1346278A (en) | Regulation of anaesthesia | |
| JP5042419B2 (en) | Bone formation promoter and composition for promoting bone formation | |
| JPH0216288B2 (en) | ||
| CN1708308A (en) | Use of fosinopril to reduce cardiovascular events in dialysis patients | |
| MXPA00002395A (en) | Method of increasing bone volume | |
| MXPA00002394A (en) | Method of increasing bone volume using non-naturally-occurring fp selective agonists | |
| CN1319528C (en) | Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure and other age-related dysfunctions of organs, age-related diseases and for | |
| CZ2000808A3 (en) | Use of selective FP agonist, which does not occur naturally | |
| JP2002538122A (en) | Methods for increasing bone volume using non-naturally occurring FP selective agonists and bone resorption inhibiting compounds | |
| CN1433302A (en) | Use of cortisol antagonists in the treatment for heat failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |